NAD+ and the Science of Raising It: What Actually Happens When You Try

Introduction

Somewhere around 2021, a molecule almost nobody outside a biochemistry department had heard of started showing up in podcast intros, supplement store endcaps, and group chats among people who track their own sleep scores. NAD+ went from a textbook footnote to a word people use the way they use "electrolytes," as if everyone already agrees on what it does and why you need more of it.

The pitch is seductive. A single molecule sits at the center of how every cell in your body makes energy, repairs its own DNA, and ages. Raise it, the argument goes, and you're addressing something close to the root cause of getting older. David Sinclair built a public career partly on this idea. A cottage industry of NMN and NR capsules followed. IV clinics added NAD+ drips next to their vitamin B12 shots.

Ask a metabolism researcher who actually runs these trials whether raising NAD+ makes people measurably better off, though, and you get something far more careful than what's on the supplement label. Some of what's happening in the clinical literature is genuinely interesting. Some of what the longevity community reports lines up with it. A fair amount doesn't, yet. This is an attempt to sort out which is which, using real trials rather than marketing copy, and real user reports rather than the five-star reviews a company chooses to feature.

What NAD+ Actually Does

NAD+, short for nicotinamide adenine dinucleotide, isn't a hormone, a peptide, or a vitamin in the usual sense. It's a coenzyme, which means it doesn't do much on its own. Its job is to shuttle electrons between the chemical reactions that keep a cell alive, and it's involved in an almost absurd number of them.

Here's the clearest way to picture it. Nearly every calorie you eat eventually gets converted into ATP, the molecule your cells spend as energy currency, inside the mitochondria. That conversion runs on a relay of electron handoffs, and NAD+ is one of the two main runners in that relay: it picks up electrons (becoming NADH), drops them off at the next step, then goes back for more, thousands of times a second, in every one of your roughly 37 trillion cells. No functioning NAD+/NADH cycle, no ATP, no energy. That part isn't controversial. It's basic biochemistry that's been understood for decades.

What's newer is the attention on NAD+'s side jobs. Two families of enzymes depend on having enough free NAD+ around to do their work. Sirtuins are a group of proteins (SIRT1 through SIRT7 in humans) that regulate gene expression, mitochondrial function, and cellular stress responses, the same sirtuins that got famous through resveratrol research in the 2000s. They can't function without NAD+ as a substrate. Less available NAD+ means less sirtuin activity, roughly speaking. PARP enzymes (poly-ADP-ribose polymerases) are the cell's DNA repair crew. Every time a strand of DNA breaks, which happens constantly from UV exposure, normal metabolic byproducts, or simple cell division, PARP enzymes show up and start patching it, consuming NAD+ as they go. A cell under heavy DNA-damage stress can burn through a meaningful chunk of its NAD+ supply on PARP activity alone.

That's the mechanistic case for why NAD+ might matter for aging: if NAD+ declines, sirtuin activity and DNA repair capacity decline with it, at exactly the biological processes most associated with getting older. And NAD+ does measurably decline. Human studies have found tissue NAD+ levels drop by roughly 50% or more between young adulthood and old age, depending on the tissue studied. One increasingly well-supported explanation for why involves an enzyme called CD38, which breaks down NAD+ and becomes dramatically more active with age, partly driven by immune cells that accumulate in aging tissue. Researchers working with mice bred to lack CD38 found those mice kept youthful NAD+ levels and mitochondrial function well into old age, a strong clue, in animals, about one mechanism behind the decline.

None of that proves that pushing NAD+ back up in a living, aging human reverses anything. A blood test showing higher NAD+ after you take a supplement tells you the supplement did something to your NAD+ metabolism. It doesn't, by itself, tell you that you'll feel better, perform better, or live longer. That gap, between raising a biomarker and changing something that actually matters to you, is where most of the real debate about NAD+ lives. It's worth holding onto through everything that follows.

A quick vocabulary check, because the terms get used loosely. NAD+ is the oxidized, electron-accepting form of the molecule. NADH is the reduced form, after it's picked up electrons; the two are constantly converting back and forth. Nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are both precursor molecules, smaller building blocks your cells convert into NAD+ through a few enzymatic steps. Neither one is NAD+. They're inputs to a pathway that produces it. Niacin (vitamin B3) and nicotinamide are older, cheaper, well-studied NAD+ precursors sitting further up the same pathway. Niacin is the one that causes the classic skin-flushing reaction at higher doses; nicotinamide generally doesn't.

Why NAD+ Became the Longevity World's Favorite Molecule

The excitement has real roots, even if the marketing outran the evidence. Sirtuin biology connected NAD+ to the same research lineage that made resveratrol a household name a decade earlier. Mitochondrial aging research kept turning up NAD+ as a recurring bottleneck. Animal studies, more on those shortly, showed striking effects on markers of aging in mice. And David Sinclair's public profile, between his Harvard lab, his books, and a near-constant podcast circuit, turned a niche area of metabolism research into something a casual listener could suddenly have an opinion about.

It landed in a few overlapping communities for slightly different reasons. In longevity medicine, it fit a broader approach built around rapamycin and metformin, trying to address root causes of aging rather than individual diseases. In biohacking circles, it offered something concrete to measure and optimize. Athletes and recovery-focused users were drawn in by the mitochondrial-energy angle. People already using peptides for recovery or hormone optimization often treated it as a natural adjacent intervention, another lever in the same general toolkit.

None of that is evidence the lever actually does what people hope. Popularity and plausibility aren't the same thing as proof, and NAD+ is a useful case study in how fast a biologically reasonable idea can outrun the data confirming it.

What the Human Research Actually Shows

This is the part that matters most, and it's also where things get genuinely mixed, not uniformly disappointing, not uniformly exciting. Here's what the actual trials found, organized by what they tested and what came out the other end.

NMN and muscle insulin sensitivity. This is the strongest human signal so far. A 2021 trial out of Washington University, led by Mihoko Yoshino and published in Science, gave 250 mg/day of NMN to 25 postmenopausal women with prediabetes who were overweight or obese, for 10 weeks, against placebo. The headline result: insulin sensitivity in skeletal muscle improved by about 25%. That's a real, clinically meaningful effect in a tissue that matters a great deal for metabolic health. But the same study found no improvement in liver or fat-tissue insulin sensitivity, no change in body weight or composition, and, oddly, no statistically significant increase in blood NAD+ itself, despite the metabolic benefit. The researchers' own interpretation was that NMN was likely improving insulin signaling machinery in muscle somewhat independently of a simple "more NAD+ in the blood" story. It's a genuinely interesting result. It's also 25 people, over 10 weeks, in one specific population.

NMN, walking speed, and sleep. This is a more recent and broader signal. A 2024 trial by Morifuji and colleagues, published in GeroScience, gave 250 mg/day of NMN to 60 Japanese adults aged 65 to 75 for 12 weeks. Blood NAD+ and its metabolites rose significantly. Gait speed, a measure researchers take seriously as a marker of functional aging, improved significantly relative to placebo. Sleep quality scores improved too, specifically on measures of daytime dysfunction. No adverse effects tied to the supplement were reported. This is one of the better-designed human trials on NMN to date, and one of the few that ties a biomarker change to something a person would actually notice in daily life.

NMN safety and pharmacokinetics. Before anyone ran efficacy trials, researchers needed to know NMN was safe to give people at all. A 2020 Japanese trial (Irie et al., Endocrine Journal) gave single doses of 100, 250, and 500 mg of NMN to 10 healthy men and tracked them for five hours. No meaningful changes in heart rate, blood pressure, or other vital signs. A few lab values shifted slightly, small increases in bilirubin, small decreases in creatinine and glucose, but stayed within normal range regardless of dose. This was never designed to show benefit, only that NMN doesn't do anything alarming in the short term. It didn't.

Nicotinamide riboside: the mixed middle. NR has been studied more than NMN in humans, largely because it reached the market earlier, and the picture is more sobering. A landmark 2018 trial from Charles Brenner's and the University of Colorado's Craig Martens's research groups (Nature Communications) gave 30 healthy middle-aged and older adults 1,000 mg/day of NR for six weeks in a crossover design. NAD+ metabolites rose substantially and stayed elevated; the compound reliably does what it's supposed to do to the biomarker. There was a modest trend toward lower blood pressure and arterial stiffness. But across a wide battery of other measures, insulin sensitivity, glucose metabolism, inflammatory markers, motor function, exercise capacity, nothing moved. A 2018 Danish trial told a similar story (Dollerup et al., American Journal of Clinical Nutrition): 2,000 mg/day of NR for 12 weeks in obese, insulin-resistant men was safe and well tolerated, and didn't improve insulin sensitivity, glucose handling, resting energy expenditure, or body composition. A 2019 crossover trial in aged men (Elhassan et al., Cell Reports) found NR raised the muscle NAD+ metabolome and lowered circulating inflammatory markers after just 21 days, a real anti-inflammatory signal, but mitochondrial bioenergetics and whole-body metabolism stayed unchanged.

NR safety, at scale. A 2019 trial (Conze et al., Scientific Reports) tested three doses of NR, 100, 300, and 1,000 mg/day, against placebo in 140 healthy, middle-aged adults over eight weeks. There was no meaningful difference in adverse events between any dose group and placebo, and no negative effect on LDL cholesterol. NAD+ metabolites rose within two weeks and stayed up for the duration. This remains one of the better safety datasets in the NAD+ precursor literature, precisely because it wasn't trying to prove an effect, just establish that the compound doesn't do harm at these doses.

Sorting all of that into honest buckets:

Fairly well supported. NR and NMN reliably raise blood or muscle NAD+ metabolites at commonly studied doses. Both are well tolerated at those doses over weeks to a few months, with a favorable safety profile across multiple independent trials.

Promising but early. NMN's effect on muscle insulin sensitivity in a prediabetic population. NMN's effect on gait speed and sleep quality in older adults. NR's modest effect on blood pressure and arterial stiffness. NR's anti-inflammatory signal in aged muscle.

Not yet demonstrated in humans. Meaningful improvements in whole-body glucose metabolism or insulin sensitivity from NR specifically. Any human lifespan extension from either compound (no trial has run anywhere near long enough to test this, and practically speaking, none could). Clear, consistent cognitive benefits. A settled answer on whether raising blood NAD+ itself, independent of other mechanisms, is what's driving the benefits researchers do see.

What Animal Research Suggests, and Why It Generated So Much Excitement

The mouse data is where a lot of the longevity-world enthusiasm actually originates, and it's worth being direct about that lineage, because the jump from mouse to human claim happens constantly in NAD+ marketing and it shouldn't.

A widely cited 2016 study from the Imai lab (Mills et al., Cell Metabolism) gave mice NMN continuously for 12 months, spanning most of their adult lifespan. The treated mice showed less age-related weight gain, better energy metabolism, more physical activity, improved insulin sensitivity, a better lipid profile, and better eye function compared to untreated mice, a broad healthspan benefit by several measures. What it did not show was a significant extension of median lifespan. The mice lived about as long; they just appeared to function better along the way. That nuance gets dropped constantly in secondary coverage. "NMN extends lifespan in mice" isn't quite what this particular landmark study found.

Other animal work has pointed to NAD+ decline as a driver of mitochondrial dysfunction (the CD38 research mentioned earlier), muscle stem cell function, and, in some studies, markers associated with neurodegeneration. There's also a less-discussed counter-note: at least one study found NR supplementation induced anxiety-like behavior in aged mice, a reminder that more NAD+ isn't automatically better across every system being studied, even in animals.

None of this is nothing. It's a coherent, biologically plausible story that NAD+ metabolism matters for aging in mammals. But mice aren't small humans, mouse lifespans are compressed in ways that make effects easier to detect, and a result that holds up cleanly in a C57BL/6 mouse colony has a long history of not translating directly to people. Every claim in this section describes what happened in rodents. None of it should be read as a human outcome.

What People Using NAD+ Are Actually Saying

Clinical trials run on a few dozen carefully screened people over a few weeks or months. The much larger, messier dataset is the tens of thousands of people who've simply bought NMN or NR and started taking it, and what they report is worth taking seriously as a pattern, not as proof, but as a signal about what's actually happening outside a research protocol.

An interesting pattern shows up across product reviews and community discussion. A meaningful share of users describe noticing something, usually steadier energy through the day, less of a mid-afternoon crash, occasionally better sleep, somewhere in the two-to-four-week window, which roughly tracks the timeline in which NAD+ metabolites actually rise in the blood. One long-time nicotinamide riboside user's account, posted after stopping the supplement for about a month, put it plainly: without it, they went back to needing a nap to get through the day, and restarted.

The negative and neutral reports are just as common, and an honest accounting has to include them. "Felt no benefit whatsoever" after months of consistent use isn't a rare review to find. Among people who do report side effects, the most frequently mentioned are mild and gastrointestinal: some nausea, stomach discomfort, occasional headache, generally described as transient. A smaller number of users describe something closer to overstimulation, jitteriness, trouble falling asleep if taken late in the day, or in rare cases a subjective sense of anxiety. That experience hasn't been clearly demonstrated in controlled human trials, though the one animal study mentioned above did find anxiety-like behavior with NR in aged mice, a plausible but unconfirmed thread connecting the two.

What doesn't show up much in user reports, interestingly, is the specific thing the strongest clinical trial actually found. Nobody's writing "my muscle insulin sensitivity improved 25%" on a product review page, because that's not something a person can feel. The mismatch between what trials measure and what users notice is itself informative, and it's exactly what the next section is about.

The Research vs. The Community

Putting the two data sets side by side makes the gap clearer than either does alone.

Community claim: "I have way more energy since starting NMN." Research: NAD+ precursors reliably raise NAD-related metabolites. Subjective energy wasn't a primary endpoint in most major trials, and the trials that did look at related measures, exercise capacity, physical performance, found effects in some populations (older adults, the gait-speed trial) and nothing in others (healthy middle-aged adults in the Martens trial). The biomarker change is consistent. The energy translation is inconsistent.

Community claim: "It fixed my sleep." Research: One well-designed trial (Morifuji et al.) found a real improvement in sleep quality scores in older adults. That's a genuine data point, not a myth, but it's a single trial in one population, not an established, reproduced effect.

Community claim: "This is basically anti-aging in a capsule." Research: No human trial has measured, or could reasonably measure on any realistic timeline, whether NAD+ precursors extend human lifespan. The mouse healthspan data is real and interesting. It is not evidence of a human anti-aging effect.

Community claim: "NR didn't do anything for me." Research: This lines up uncomfortably well with several of the better-controlled human trials, particularly in metabolically healthy populations. Martens and Dollerup both found NR reliably raises NAD+ metabolites while leaving most measured health outcomes unchanged. A null personal experience with NR specifically isn't surprising. It's close to what multiple RCTs already found.

Community claim: "I felt worse, nausea and jitteriness." Research: The controlled trials themselves largely found no significant difference in adverse events versus placebo at commonly used doses. That's a real tension worth sitting with. Either the trial populations (healthy volunteers, carefully dosed) differ meaningfully from the self-selected, self-dosed real-world population, or at least some of what gets attributed to NAD+ supplements in casual use is something else: product quality, dose, timing, or expectation.

When People Say They "Feel NAD+," and Why Others Feel Nothing

If the biology is consistent, why does the subjective experience vary so much from one person to the next? Nobody has a definitive answer, but a few explanations are biologically reasonable, and it's worth being clear about which of these are proven mechanisms and which are informed guesses.

Baseline NAD+ status is the most obvious candidate. Someone who's older, more metabolically unwell, or under more chronic physiological stress has further to climb, and per the CD38 research, is likely losing NAD+ faster to begin with, which means there's simply more room for a measurable change. A healthy 28-year-old with normal NAD+ metabolism may be raising a number that wasn't particularly deficient in the first place. This is a hypothesis grounded in real mechanistic data, not a proven dose-response relationship in humans.

Sleep debt, diet, and exercise habits plausibly interact with NAD+ metabolism in ways that haven't been cleanly isolated in trials. Someone who's chronically under-slept and fixes that at the same time they start NMN has a confound sitting right next to the supplement. Differences between NR and NMN in how they're absorbed could matter too: NR is partly broken down to plain nicotinamide before it ever reaches the bloodstream intact, and whether NMN gets taken up directly by cells via a dedicated transporter is still debated in human tissue, even though it's been identified in mice. Dose matters in ways that haven't been fully mapped. Most human trials cluster between 250 mg and 1,000 mg daily, and nobody has run a clean dose-response study measuring subjective outcomes.

And then there's the explanation nobody likes bringing up first but has to be on the list: expectation. A supplement marketed heavily around energy and vitality, taken by someone primed to notice a change, will generate some number of real reports that are physiologically unrelated to the molecule itself. That doesn't make every positive report fake. It does mean a mix of real biology and real placebo response is almost certainly happening at the population level, and no current research cleanly separates the two for NAD+ precursors specifically.

Safety and Side Effects

Across the controlled human trials described above, both NR and NMN have a reassuring safety record at the doses studied, typically 250 mg to 2,000 mg daily, for periods ranging from a few weeks to several months. The most consistently reported adverse effects, where they appear at all, are mild: gastrointestinal discomfort, nausea, and headache, generally not statistically different from placebo rates. Flushing, the hallmark side effect of plain niacin, hasn't been a consistent finding with NR or NMN specifically. No trial to date has reported a serious adverse event clearly attributable to either compound at commonly studied doses.

What's genuinely unknown is anything past the multi-month mark. The longest controlled human trials on NAD+ precursors run around 12 weeks. Nobody has published data on what three or five years of continuous supplementation does, because that trial largely doesn't exist yet.

The theoretical concern worth taking seriously, not sensationalizing, involves cancer biology. NAD+ is essential to normal cellular survival, and PARP-mediated DNA repair depends on it. That's true in healthy cells, and it's also true in cancer cells, which tend to have unusually high NAD+ turnover to support their own rapid proliferation and DNA repair needs. An enzyme called NAMPT, which helps regenerate NAD+ inside cells, has been studied as a legitimate cancer drug target precisely because blocking it starves tumor cells of the NAD+ they need to keep dividing and repairing damage. That research is real, and it's the reason some clinicians raise an eyebrow at long-term NAD+ elevation in anyone with an active or recent cancer history.

None of that means NAD+ supplementation causes cancer. There's no human data showing that. The mechanistic concern is about feeding an existing or developing tumor's NAD+-dependent machinery, not about NAD+ supplementation initiating cancer in a healthy cell, a meaningfully different claim, and one without evidence behind it either way in long-term human populations. What follows from the uncertainty, not from a proven risk, is straightforward: anyone with a personal or strong family history of cancer, anyone currently in cancer treatment, pregnant or breastfeeding people, and anyone on medications with real interaction potential should talk to a doctor who knows their history before starting NAD+ precursors. Not because something bad is known to happen, but because the honest answer to "is this safe long-term in my specific situation" doesn't exist yet in the research.

Dosage and Real-World Protocols

Injectable (subcutaneous) NAD+. This is reconstituted NAD+ powder, injected subcutaneously, the same general format as compounds like BPC-157 or TB-500 rather than a capsule, which is the form actually sold and used this way. No published human clinical trial has established a standardized subcutaneous NAD+ dose, so nothing here carries the same evidence weight as the human trial data discussed earlier in this piece, all of which studied oral precursors. What exists instead comes from clinical and compounding practice and from how people in peptide and biohacking communities actually use it, which is worth laying out plainly since it's real information people are using right now, just not research-validated information.

Commonly reported practice starts conservatively, somewhere around 20 to 50 mg per injection, and titrates up toward 50 to 100 mg per injection as it's tolerated, typically one to three times per week. Some protocols front-load with a short daily phase, roughly 100 to 200 mg per day for about a week to ten days, before stepping down to that weekly range for maintenance. Injection volume generally runs 0.5 to 1 mL per dose, given subcutaneously into abdominal fat, the thigh, or the back of the upper arm. None of these numbers come from a controlled trial. They're a snapshot of current practice, reported by clinics and compounding sources and echoed in community discussion, and they vary enough from one source to the next that "typical" is doing real work in that sentence. Start low, go slow, and treat any specific protocol a vendor or clinic hands you as their own extrapolation rather than an established medical dose.

Compound/Route	Typical Research Dose	Study Duration	Evidence Level	Notes
NAD+ (subcutaneous)	50–100 mg per injection, 1–3x/week (some protocols load at 100–200 mg/day for ~1 week first)	N/A, no controlled trials	Clinical practice / community-reported	Real-world protocol, not research-derived; doses vary meaningfully by source

What We Still Don't Know

A lot, honestly, and that's worth saying plainly rather than papering over. Does raising NAD+ extend human lifespan? Nobody knows. The trial that could answer that would need to run for decades. Does it meaningfully improve healthspan in otherwise healthy people, versus the specific older or metabolically unwell populations studied so far? Unclear. Is there an optimal NAD+ level to target, the way there's a target range for blood pressure or LDL cholesterol? No such target has been established. Does NAD+ need to be raised continuously to matter, or do intermittent or cyclical protocols work as well? Nobody has tested this directly. Does the response change meaningfully with age, and is a 70-year-old's and a 35-year-old's realistic benefit the same thing? The limited data we have suggests older, less metabolically healthy populations see more measurable effects, but that's a pattern across a handful of trials, not a settled finding.

Are NR and NMN functionally equivalent, or does the delivery route and conversion pathway produce meaningfully different effects? No head-to-head human trial has compared them directly on a clinical outcome. Do the subjective energy and sleep improvements some people report actually track with measurable physiological change in those same individuals, or are they running on separate tracks? And probably the most practically important open question: what happens with years of continuous use, in either direction, benefit or harm, when nobody has published data past about three months?

That's a long list of unknowns for a molecule this heavily marketed. It doesn't mean the underlying biology is wrong. It means the confident claims circulating in longevity media are running well ahead of what's actually been nailed down, and anyone deciding whether this is worth their money and attention deserves to know exactly where that line sits.

Sources

1. Yoshino M, et al. "Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women." Science 372(6547):1224-1229, 2021.
2. Morifuji M, et al. "Ingestion of β-nicotinamide mononucleotide increased blood NAD levels, maintained walking speed, and improved sleep quality in older adults in a double-blind randomized, placebo-controlled study." GeroScience, 2024.
3. Irie J, et al. "Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men." Endocrine Journal 67(2):153-160, 2020.
4. Martens CR, et al. "Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults." Nature Communications 9:1286, 2018.
5. Dollerup OL, et al. "A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects." American Journal of Clinical Nutrition 108(2):343-353, 2018.
6. Elhassan YS, et al. "Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD+ Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures." Cell Reports 28:1717-1728, 2019.
7. Conze D, Brenner C, Kruger CL. "Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults." Scientific Reports 9:9772, 2019.
8. Mills KF, et al. "Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice." Cell Metabolism 24:795-806, 2016.
9. Camacho-Pereira J, et al. "CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism." Cell Metabolism 23:1127-1139, 2016.
10. Product review and community-reported user experiences (Trustpilot, consumer and forum discussion), cited throughout as anecdotal, not clinical, evidence.

This content is for informational purposes only and is not medical advice. NAD+ precursors discussed here are not FDA-approved for the treatment of any condition. Speak with a qualified healthcare provider before starting any NAD+-raising supplement, especially if you have a personal or family history of cancer, are pregnant or breastfeeding, or take other medications.